Katharina V Schulze1, Amit Bhatt2, Mahshid S Azamian1, Nathan C Sundgren2, Gladys E Zapata2, Patricia Hernandez2, Karin Fox1,3, Jeffrey R Kaiser2,3, John W Belmont1,2,4, Neil A Hanchard5,6. 1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. 2. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 3. Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA. 4. USDA/ARS/Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA. 5. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. hanchard@bcm.edu. 6. USDA/ARS/Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA. hanchard@bcm.edu.
Abstract
PURPOSE: Maternal diabetes is a known teratogen that can cause a wide spectrum of birth defects, collectively referred to as diabetic embryopathy (DE). However, the pathogenic mechanisms underlying DE remain uncertain and there are no definitive tests to establish the diagnosis. Here, we explore the potential of DNA methylation as a diagnostic biomarker for DE and to inform disease pathogenesis. METHODS: Bisulfite sequencing was used to identify gene regions with differential methylation between DE neonates and healthy infants born with or without prenatal exposure to maternal diabetes, and to investigate the role of allele-specific methylation at implicated sites. RESULTS: We identified a methylation signature consisting of 237 differentially methylated loci that distinguished infants with DE from control infants. These loci were found proximal to genes associated with Mendelian syndromes that overlap the DE phenotype (e.g., CACNA1C, TRIO, ANKRD11) or genes known to influence embryonic development (e.g., BRAX1, RASA3). Further, we identified allele-specific methylation (ASM) at 11 of these loci, within which 61.5% of ASM single-nucleotide variants are known expression quantitative trait loci (eQTLs). CONCLUSIONS: Our study suggests a role for aberrant DNA methylation and cis-sequence variation in the pathogenesis of DE and highlights the diagnostic potential of DNA methylation for teratogenic birth defects.
PURPOSE: Maternal diabetes is a known teratogen that can cause a wide spectrum of birth defects, collectively referred to as diabetic embryopathy (DE). However, the pathogenic mechanisms underlying DE remain uncertain and there are no definitive tests to establish the diagnosis. Here, we explore the potential of DNA methylation as a diagnostic biomarker for DE and to inform disease pathogenesis. METHODS: Bisulfite sequencing was used to identify gene regions with differential methylation between DE neonates and healthy infants born with or without prenatal exposure to maternal diabetes, and to investigate the role of allele-specific methylation at implicated sites. RESULTS: We identified a methylation signature consisting of 237 differentially methylated loci that distinguished infants with DE from control infants. These loci were found proximal to genes associated with Mendelian syndromes that overlap the DE phenotype (e.g., CACNA1C, TRIO, ANKRD11) or genes known to influence embryonic development (e.g., BRAX1, RASA3). Further, we identified allele-specific methylation (ASM) at 11 of these loci, within which 61.5% of ASM single-nucleotide variants are known expression quantitative trait loci (eQTLs). CONCLUSIONS: Our study suggests a role for aberrant DNA methylation and cis-sequence variation in the pathogenesis of DE and highlights the diagnostic potential of DNA methylation for teratogenic birth defects.
Entities:
Keywords:
allele-specific methylation; bisulfite sequencing; diabetic embryopathy; infant of a diabetic mother; teratogens
Authors: Jeanne S Sheffield; Erin L Butler-Koster; Brian M Casey; Donald D McIntire; Kenneth J Leveno Journal: Obstet Gynecol Date: 2002-11 Impact factor: 7.661
Authors: Erfan Aref-Eshghi; Jennifer Kerkhof; Victor P Pedro; Mouna Barat-Houari; Nathalie Ruiz-Pallares; Jean-Christophe Andrau; Didier Lacombe; Julien Van-Gils; Patricia Fergelot; Christèle Dubourg; Valerie Cormier-Daire; Sophie Rondeau; François Lecoquierre; Pascale Saugier-Veber; Gaël Nicolas; Gaetan Lesca; Nicolas Chatron; Damien Sanlaville; Antonio Vitobello; Laurence Faivre; Christel Thauvin-Robinet; Frederic Laumonnier; Martine Raynaud; Mariëlle Alders; Marcel Mannens; Peter Henneman; Raoul C Hennekam; Guillaume Velasco; Claire Francastel; Damien Ulveling; Andrea Ciolfi; Simone Pizzi; Marco Tartaglia; Solveig Heide; Delphine Héron; Cyril Mignot; Boris Keren; Sandra Whalen; Alexandra Afenjar; Thierry Bienvenu; Philippe M Campeau; Justine Rousseau; Michael A Levy; Lauren Brick; Mariya Kozenko; Tugce B Balci; Victoria Mok Siu; Alan Stuart; Mike Kadour; Jennifer Masters; Kyoko Takano; Tjitske Kleefstra; Nicole de Leeuw; Michael Field; Marie Shaw; Jozef Gecz; Peter J Ainsworth; Hanxin Lin; David I Rodenhiser; Michael J Friez; Matt Tedder; Jennifer A Lee; Barbara R DuPont; Roger E Stevenson; Steven A Skinner; Charles E Schwartz; David Genevieve; Bekim Sadikovic Journal: Am J Hum Genet Date: 2020-02-27 Impact factor: 11.025
Authors: Kang Li; Yi Song; Ling Qin; Ang Li; Sanjie Jiang; Lei Ren; Chaoran Zang; Jianping Sun; Yan Zhao; Yonghong Zhang Journal: Front Oncol Date: 2021-10-20 Impact factor: 6.244